이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder (URIS-1)

2026년 11월 10일 업데이트: Zuzana Jirásková, General University Hospital, Prague

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial

This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.

Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.

The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.

연구 유형

중재적

등록 (추정된)

47

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Prague, 체코, 128 08
        • 모병
        • General University Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

7년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Children aged 7 to 12 years, boys and girls
  • Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
  • At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
  • No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
  • Ability and willingness of the child and the parent to follow the protocol; signed informed consent

Exclusion Criteria:

  • Severe daytime incontinence (complete wetting in more than 50% of episodes)
  • Anticholinergic treatment for overactive bladder in the last 3 months
  • Neurogenic lower urinary tract dysfunction
  • Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
  • Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
  • Local lesions of the lower limbs (skin disease, osteosynthesis material)
  • Peripheral neuropathy of the lower limbs
  • Presence of an electronic implant in the body (e.g., a neurostimulator)
  • Functional constipation during the previous 3 months (Rome III-IV criteria)
  • Symptomatic urinary tract infection

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Active stimulation

Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks.

Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.

가짜 비교기: Sham stimulation

Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks.

Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of clinical responders at the end of treatment
기간: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

A clinical responder is a child who meets either or both of the following criteria at the end of treatment:

  1. a reduction of at least 50% in the number of wet days during waking hours over 14 days of the wetting diary compared with baseline;
  2. a PGI-I score of 2 or less rated by both the parent and the child. PGI-I (Patient Global Impression of Improvement) ranges from 1 = very much better to 7 = very much worse.
Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

2차 결과 측정

결과 측정
측정값 설명
기간
Change in the number of daytime incontinence episodes per 24 hours
기간: Baseline, Week 6, Week 12

Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the severity of daytime incontinence episodes
기간: Baseline, Week 6, Week 12

Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the number of wet days
기간: Baseline, Week 6, Week 12

Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline.

Baseline, Week 6, Week 12
Change in micturition frequency and functional bladder capacity
기간: Baseline, Week 6, Week 12

Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline.

Baseline, Week 6, Week 12
Change in DVISS total score (parent-rated)
기간: Baseline, Week 6, Week 12

Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms.

Baseline, Week 6, Week 12
Change in Bower PIN-Q total score (child-rated)
기간: Baseline, Week 6, Week 12

Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline.

Baseline, Week 6, Week 12
PGI-I score rated by the child and by the parent
기간: Week 6, Week 12

Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse).

Week 6, Week 12
CGI-I score rated by the unblinded investigator
기간: Week 6, Week 12

Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse).

Week 6, Week 12
Number, type and severity of treatment-related adverse events
기간: From the first stimulation to Week 12

Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit.

From the first stimulation to Week 12
Adherence to treatment
기간: Week 12

Proportion of participants who attend at least 80% of the 12 planned stimulation sessions.

Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Zuzana Jiraskova, MD, FEAPU, General University Hospital, Prague

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 3일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • Uris_01_2026
  • 000058 (기타 식별자: ISZP)
  • sukls114680/2026 (기타 식별자: State Institute for Drug Control (SUKL))
  • sukl222573/2026 (기타 식별자: State Institute for Drug Control (SUKL))
  • 376/26 A, IB, D, PS (기타 식별자: Ethics Committee, General University Hospital in Prague)
  • 443/26 A, IB (기타 식별자: Ethics Committee, General University Hospital in Prague)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .